If you have been reading about human growth hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
=== Effects of cooking === The USDA has conducted extensive studies on the percentage losses of various nutrients from food types and cooking methods. Some vitamins may become more "bio-available" – that is, usable by the body – when foods are cooked. The table below shows whether various vitamins are susceptible to loss from heat—such as heat from boiling, steaming, frying, etc. The effect of cutting vegetables can be seen from exposure to air and light. Water-soluble vitamins such as B and C dissolve into the water when a vegetable is boiled, and are then lost when the water is discarded.
== Other sources == Simoni RD, Hill RL, Vaughan M (August 2002). "Copper as an essential nutrient and nicotinic acid as the anti-black tongue (pellagra) factor: the work of Conrad Arnold Elvehjem". The Journal of Biological Chemistry. 277 (34): e22. doi:10.1016/S0021-9258(20)70109-2. ISSN 0021-9258. PMID 12185207. Elvehjem CA, Madden RJ, Strong FM, Woolley DW (February 1974). "The isolation and identification of the anti-black tongue factor". Nutrition Reviews. 32 (2): 48–50. doi:10.1111/j.1753-4887.1974.tb06263.x. ISSN 0029-6643. PMID 4274128. S2CID 7197859. Harper AE, Elvehjem CA (August 1991). "Journal of the American Medical Association, Volume 158, 1955: Importance of amino acid balance in nutrition". Nutrition Reviews. 49 (8): 233–4. doi:10.1111/j.1753-4887.1991.tb03034.x. ISSN 0029-6643. PMID 1956589. Burris RH, Baumann CA, Potter VR (1990). "Conrad Arnold Elvehjem: May 27, 1901 – July 27, 1962". Biographical Memoirs of the National Academy of Sciences. 59: 135–67. PMID 11616156. Todd W, Elvehjem C, Hart E (April 1980). "Zinc in the Nutrition of the Rat". Nutrition Reviews. 38 (4): 151–4. doi:10.1111/j.1753-4887.1980.tb05879.x. ISSN 0029-6643. PMID 7010227. Kline OL, Baumann CA (May 1971). "Conrad Arnold Elvehjem--a biographical sketch (1901–1962)". The Journal of Nutrition. 101 (5): 571–7. doi:10.1093/jn/101.5.569. ISSN 0022-3166. PMID 4930952.
== Investigative applications == In bioarchaeological research and in forensic investigations, osteons in a bone fragment can be used to determine the sex of an individual and age, as well as aspects of taxonomy, diet, health and motor history. Osteons and their arrangement vary according to taxon, so that genus and sometimes species can be differentiated using a bone fragment not otherwise identifiable. However, there is considerable variability among the different bones of a skeleton, and features of some faunal osteons overlap with those of human osteons; therefore, examination of osteons is not of primary use in the analyses of osteological remains. More research is needed, but osteohistology has the potential to positively affect the studies in bioarchaeology, paleontology and forensic investigations. In recent decades, osteohistological studies of dinosaur fossils have been used to address a number of issues, such as the periodicity of growth of dinosaurs and whether it was uniform across species and the question of whether dinosaurs were warm-blooded or not.
Sources: en.wikipedia.org
The Gateway Program is the planned expansion and renovation of the Northeast Corridor between Newark, New Jersey, and New York City to alleviate the bottleneck by allowing for refurbishment of the existing North River Tunnels and ultimately expanding the right-of-way to four tracks, doubling the capacity of Penn Station. Two new tunnels under the Hudson River would add 25 cross-Hudson train slots during rush hours. Some proposals anticipated a four-platform, seven-track expansion of Penn Station with a new annex to the south to take advantage of the new capacity, but current reconstruction plans envision increasing capacity through some limited through-running instead. The Gateway Program was unveiled in 2011, one year after the cancellation of the somewhat-similar Access to the Region's Core (ARC) project, and was originally projected to cost $13.5 billion and take 14 years to build. Construction of a "tunnel box" to preserve right-of-way on Manhattan's West Side began in September 2013. In 2015, Amtrak said that damage done to the existing trans-Hudson tunnels by Sandy had made their replacement urgent and reported that design work on the tunnel component was underway, estimating the project cost at $20 billion. A draft environmental impact statement on the Hudson Tunnel project was released in July 2017, but the first Trump administration delayed consideration of it. Unblocking the project was a stated priority of the Biden administration, and the project was approved in May 2021.
=== Redox biology and drug metabolism in disease and therapeutics === Townsend has made contributions to the field of biochemistry, particularly in the context of oxidative stress, redox regulation, and their implications in various diseases. Exploring the impact of oxidative stress and redox regulation on cellular differentiation, she investigated their role in diseases associated with abnormal cell differentiation. In a collaborative study with Tapiero and Tew, she provided details on carotenoids as dietary antioxidants, highlighting their role in preventing cancer and cardiovascular diseases by mitigating oxidative damage and promoting intercellular communication. She also identified S-glutathionylation as a cell stress indicator and unfolded protein response regulator, linking it to pathologies and potential therapies influenced by oxidative stress and endoplasmic reticulum redox conditions. In another joint study, her work delved into the role of cysteine S-glutathionylation in redox cell signaling, proposing it as a biomarker for oxidative/nitrosative stress and its utility for individuals exposed to stress-inducing agents affecting protein clusters. Townsend's research has discussed the multifaceted role of glutathione S-transferase P (GSTP) in mediating S-glutathionylation, negatively regulating kinase pathways, and contributing to cellular redox homeostasis, with implications for drug development.
Epelsiban (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, code name GSK-557,296-B) is an orally bioavailable and peripherally selective drug which acts as a selective and potent oxytocin receptor antagonist (Ki = 0.13 nM). It was initially developed by GlaxoSmithKline (GSK) for the treatment of premature ejaculation in men and then as an agent to enhance embryo or blastocyst implantation in women undergoing embryo or blastocyst transfer associated with in vitro fertilization (IVF), and was also investigated for use in the treatment of adenomyosis.
"Eat Mor Chikin" is the chain's most prominent advertising slogan, created by The Richards Group in 1995. The slogan is often seen in advertisements featuring Holstein dairy cows that are often seen wearing (or holding) signs that (usually) read "Eat Mor Chikin" in capital letters. The ad campaign was temporarily halted on January 1, 2004, during a mad cow disease scare, so as not to make the chain seem insensitive or appear to be taking advantage of the scare to increase its sales. Two months later, the cows were put up again. The cows replaced the chain's old mascot, Doodles, an anthropomorphized chicken that still appears as the C on the logo. Chick-fil-A vigorously protects its intellectual property, sending cease and desist letters to those they think have infringed on their trademarks. The corporation has successfully protested at least 30 instances of the use of an "eat more" phrase, saying that the use would cause confusion of the public, dilute the distinctiveness of their intellectual property, and diminish its value. A 2011 letter to Vermont artist Bo Muller-Moore who screen prints T-shirts reading: "Eat More Kale" demanded that he cease printing the shirts and turn over his website. The incident drew criticism from Vermont governor Peter Shumlin, and created backlash against what he termed Chick-fil-A's "corporate bullying". On December 11, 2014, Bo Muller-Moore announced that the U.S. Patent Office granted his application to trademark his "Eat More Kale" phrase.
Sources: en.wikipedia.org
In his first reelection bid, Mizell defeated Democrat James G. White, 68,937 (58.1 percent) to 49,663 (41.9 percent). He was endorsed that year by Americans for Constitutional Action (ACA). Charles McManus, the ACA's president, said, "He has repeatedly stood for fiscal responsibility; firm responsible opposition to the Communists; and for law and order in our streets and institutions of learning." In a 1971 speech to Congress, Mizell voiced his support for MLB's antitrust exemption. "[T]hrough baseball, opportunities have been afforded to young men who otherwise would not have been able to fully enjoy the American dream. Baseball builds character into young men who are going to be the leaders of the future." In 1972, he trounced former Arkansas Congressman Brooks Hays, who had moved to North Carolina, 101,375 (64.8 percent) to 54,986 (35.2 percent). During this term, he was a cosponsor of House Resolution 6992, which proposed equal rights to broadcast media outlets for the chance to broadcast sporting events. In 1972, he chaired a committee that tried to set up a Billy Graham Crusade in Washington, D.C., in 1973. Mizell opposed the Appalachian Power Company's Blue Ridge Power Project, a plan to build two dams on the New River. He was concerned about the project's impact: "Changing the basis for this environmental destruction from ‘pollution‐dilution’ to ‘power crisis’ does not lessen or eliminate the environmental destruction itself...Just as much land will . . . be flooded.
syncytium Also symplasm; pl. syncytia. A multinucleate cell, i.e. a cell containing more than one nucleus or, in the broadest sense, more than one nuclear genome (a meaning which is equated with polyploidy). Syncytia may form as a result of cell fusion between uninucleate cells, migration of a nucleus from one cell to another, or multiple nuclear divisions without accompanying cytokinesis (forming a coenocyte). The term may also refer to cells which are interconnected by specialized membranes with gap junctions as in some neuromuscular cell types.
=== Anti-cancer === There are two primary mTOR inhibitors used in the treatment of human cancers, temsirolimus and everolimus. mTOR inhibitors have found use in the treatment of a variety of malignancies, including renal cell carcinoma (temsirolimus) and pancreatic cancer, breast cancer, and renal cell carcinoma (everolimus). The complete mechanism of these agents is not clear, but they are thought to function by impairing tumour angiogenesis and causing impairment of the G1/S transition.
Delegates from the member countries attend committee and other meetings. Former Deputy Secretary-General Pierre Vinde estimated in 1997 that the cost borne by the member countries, such as sending their officials to OECD meetings and maintaining permanent delegations, is equivalent to the cost of running the secretariat. The OECD regularly holds minister-level meetings and forums as platforms for a discussion on a broad spectrum of thematic issues relevant to the OECD charter, member countries, and non-member countries.
The main symptoms of RA are joint pain, swelling, and stiffness, which are usually worst in the morning or after resting. Joint affected by RA are often tender when pressed or moved. Morning stiffness can last for several hours but gradually improves with movement and physical activity.This is different from osteoarthritis, where stiffness doesn't last as long. The symptoms of RA can make it difficult to perform everyday tasks, interfere with sleep, and reduce overall quality of life. RA usually develops gradually and often begins by affecting the small joints of the hands (metacarpophalangeal and proximal interphalangeal joints) and feet before spreading to larger joints. The condition can affect any joint, tendon, or bursa that contains synovial tissue, including the elbows, shoulders, ankles, knees, hips, and jaw. RA is polyarticular, meaning it affects multiple joints. Although RA usually affects the same joints on both sides of the body, this symmetry may not be present in the early stages. RA can be difficult to detect when it first develops because inflammation of the synovial membrane (synovitis) may not be visible early on. Signs of synovitis include soft, spongy swelling around a joint. Joint deformities are not seen early in the disease but can develop over time if RA is severe, chronic, or left untreated, and can potentially lead to significant disability. As the pathology progresses, the inflammatory activity leads to tendon tethering and erosion and destruction of the joint surface, which impairs range of movement and leads to deformity.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.